VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas
- PMID: 7459900
Item in Clipboard
VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas
Cancer Treat Rep.
1980 Oct-Nov.
Abstract
VP-16-213 has been used in 5-day courses together with cyclophosphamide, doxorubicin (Adriamycin), vincristine, and prednisone for treatment of 74 consecutive patients with non-Hodgkin's lymphomas. Ninety-one percent of patients with favourable histology and 69% with unfavorable histology achieved complete or partial remissions (overall response rate of 76%). The frequency of complete remission was disappointingly low (22%), possibly due to reduction of doses of the other myelosuppressive agents in the present combination. Further trials with VP-16-213 in other combination chemotherapy are required.
Similar articles
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.Cancer J. 2000 May-Jun;6(3):146-50. Cancer J. 2000. PMID: 10882329 Clinical Trial.
-
[A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].Gan To Kagaku Ryoho. 1984 Aug;11(8):1644-8. Gan To Kagaku Ryoho. 1984. PMID: 6476837 Japanese.
-
[Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].Sem Hop. 1981 Nov 8-25;57(41-42):1685-90. Sem Hop. 1981. PMID: 6272402 French.
-
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.Cancer Treat Rep. 1977 Sep;61(6):1079-83. Cancer Treat Rep. 1977. PMID: 71207 Review.
Cited by
-
Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.Drugs. 1990 Mar;39(3):438-90. doi: 10.2165/00003495-199039030-00008. Drugs. 1990. PMID: 2184009 Review. No abstract available.
-
A phase I trial of high-dose oral tamoxifen and CHOPE.Cancer Chemother Pharmacol. 1995;36(1):65-8. doi: 10.1007/BF00685734. Cancer Chemother Pharmacol. 1995. PMID: 7720178 Clinical Trial.
-
DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.J Cancer Res Clin Oncol. 2019 Jan;145(1):117-127. doi: 10.1007/s00432-018-2771-9. Epub 2018 Oct 16. J Cancer Res Clin Oncol. 2019. PMID: 30327941 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical